MBX Biosciences, Inc. is pleased to announce the appointment of Steven Prestrelski as its Chief Scientific Officer (CSO).

With over 30 years of experience in the biopharmaceutical industry, Steven brings valuable scientific and operational expertise, particularly in endocrine and metabolism product development. Previously, he served as Founder and Chief Scientific Officer at Xeris Biopharma Holdings Inc.

MBX Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies in the field of endocrine and metabolic diseases.